Nerivio REN Wearable

Designed with adolescents in mind.

Nerivio is the first and only FDA cleared therapy to utilize Remote Electrical Neuromodulation (REN) to prevent and treat migraine. It uses non-painful stimulation to harness the natural power of the brain to control migraine pain and symptoms without drugs, needles, or disruption; even during class!

The Mechanism
of Action Explained
Nerivio

For Teens

FDA
Approved
Treat &
Prevent
Ages
8 & Up

How to prescribe Nerivio

*Contact Nerivio Cares at (937) 637-4846 if you need assistance e-prescribing.

Prescribe Nerivio using this form. Available also via e-prescription*
1
Send the prescription to ProCare Rx
2
ProCare Rx will deliver Nerivio directly to your patient
3

Prescribe Nerivio using this form. Available also via e-prescription*

Send the prescription to ProCare Rx

ProCare Rx will deliver Nerivio directly to your patient

Doctors’ Recommendations

Watch Nerivio users share their migraine journeys and Nerivio’s impact on their lives. None have been compensated for sharing their Nerivio experience.

“With Nerivio, my patients have had a life-changing quality of life. Nerivio is not a want - it’s a need. This safe treatment for migraine is a vital breakthrough. It is my responsibility to let colleagues and patients know about this important therapy.”

Kathy Fields, MD
Co-founder of Rodan+ Fields

“A large study of many patients over a lengthy period of time and multiple treatments, reinforces that REN [Nerivio] provides a safe, efficacious and stable treatment for acute migraine, both as a standalone and as an adjunct therapy."

Dr. Jessica Ailani, MD
Director of the MedStar Georgetown Headache Center and Professor of Clinical Neurology in the Department of Neurologykathy fields

“Chronic migraine patients experience more frequent and severe attacks than episodic migraine patients. Non-pharmacological interventions such as REN [Nerivio] help meet this need by providing a drug free treatment option.”

Brian M. Grosberg, MD
Director of the Hartford Healthcare Headache Program in Connecticut and Professor of Neurology at the University of Connecticut School of Medicine

“Research shows this [REN, Nerivio] to be comparable with triptans. Pain relief at 2 hours was 67%, which is better than with many triptans.”

Alan M. Rapoport, MD
Clinical Professor of Neurology at The David Geffen School of Medicine at UCLA, and a Past-President of the International Headache Society

High five for freedom from medication complications and side effects

Drug-free and non-addictive
No systemic side effects
No pills, no needles
No risk of overuse
Use alone or alongside medication 

Clinical Data: Adolescents

Pilot Study - Relief of Migraine Pain Through Electro Stimulation (NCT02453399)

The results of the pilot study were published in Neurology, March 2017:88:(13) 1250-1255.

Read More
Read More
Pivotal Study - A Randomized, Double Blinded Clinical Study to Evaluate the Safety and Efficacy of the Nerivio device, Intended to Relief Pain During Migraine episode in Subjects Suffer From Migraines (NCT03361423)

The results of the pivotal study were published in Headache, May 2019: :59(8):1240-1252.

Read More
Read More
Efficacy and safety of Nerivio, a remote electrical neuromodulation device, for acute treatment of migraine in people with chronic migraine: an open label, single arm, multicenter study (NCT 04161807)

The results of the pilot study were published in Pain and Therapy, July 2020.(9);531-543

Read More
Read More
An open label, single arm, multicenter study assessing the efficacy and safety of Nerivio, a remote electrical neuromodulation device, for acute treatment of migraine in people with chronic migraine (NCT04194998)

The results of the main study will be published in Pain Reports, November 2021. 6(4):e966

Read More
Read More
A single arm, open label, multicenter study of the safety and efficacy of Nerivio for the acute treatment of migraine in adolescents (NCT04089761)

The results of the pivotal study were published in Headache, December 2020. 61(2): 310-317

Read More
Read More
A prospective, Randomized, double-blind, sham-controlled multi-center clinical study assessing the safety and efficacy of Nerivio for the preventive treatment of migraine (NCT04828707).

The results of the pivotal study were published in Headache. 2023 Jan 27.63(3): 377-389

Read More
Read More
Prospective post marketing study of acute treatment of migraine assessing the safety and efficacy of Nerivio in children under the age of 12 (NCT06138756)

The results of the study were published in Annals of the Child Neurology Society, Volume2, Issue2 June 2024; Pages 135-145

Read More
Read More
Real-World Evidence (RWE) Data Analysis of 1-Year Consecutive Use of Nerivio (NCT05760638)

The results of the study were published in Advances in Therapy. January 2024; 41(1):170-181

Read More
Read More
Retrospective Controlled Survey Study to Assess the Safety of Treating Migraine With Nerivio During Pregnancy and 3 Months Postpartum (NCT05464069)

The results of the study were published in Headache, July-August 2023;63(7):968-970

Read More
Read More
Are you a healthcare provider seeing adolescents?

Get up to date with the latest in treating adolescents with migraine

New International Continuing Medical Education (CME) session is now available online: Unmet Needs in Treating Adolescent Migraine, by US pediatric neurologist and headache specialist Dr. Shannon Babineau.

In this one-hour CME, Dr. Babineau reviews the disease state, explains the special unmet needs of young patients, and describes available therapies, including the newest ones.

Explore the CME
1.0 CME credit
No Cost
(Disclosure: this CME was enabled through an education grant from Theranica)